UnitedHealth (UNH) has faced challenges, including the CEO’s assassination, policy practices, lawsuits, and investigations, leading to a 44% decrease in shares. Analysts have slashed price targets, citing ongoing issues at Optum. Despite setbacks, UNH has been a wealth creator, operating through UnitedHealthcare and Optum, the largest US health insurer. UNH plans to expand and meet rising healthcare demands.

UNH has operational synergies due to its scale and integrated business lines. Customer growth in UnitedHealthcare is strong, linked to tailored healthcare offerings. Optum offers stable revenue and aims to add more patients under value-based care agreements. With favorable demographics, UNH is positioned to meet growing health solution demand.

Concerns include high claims denial rate, financial pressure, and recent missed revenue and earnings estimates. Despite this, UNH reported increased revenues and earnings in Q1 2025. Cash flows surged, and the company’s valuation is comfortable. Analysts rate UNH as a “Moderate Buy” with a mean target price of $358.70, showing upside potential. UNH will report Q2 earnings on July 29.

Read more at Yahoo Finance: Analysts Are Cutting Their Price Targets for UnitedHealth Stock Before Q2 Earnings. Is It Time to Ditch Shares?